Daré Bioscience, Inc. filings document a women’s health biotechnology issuer with product and pipeline disclosures, operating-result updates, and capital-structure activity. Recent 8-K reports cover financial results, Regulation FD presentations, and unregistered sales tied to a Regulation A unit offering composed of Series A Convertible Preferred Stock and warrants to purchase common stock.
Proxy and governance filings describe annual meeting matters, director elections, executive compensation, equity awards, board classification, and stockholder voting procedures. The record also includes disclosure around offering statements, preferred-stock conversion terms, warrant exercise terms, and financing activity associated with advancing women’s health products and clinical programs.
Daré Bioscience created a new Series A Convertible Preferred Stock and launched a Regulation A offering of preferred stock and warrant units. The company designated 4,999,620 shares of preferred stock with a $5.00 stated value, no dividends, and senior liquidation rights over common stock.
Each preferred share is initially convertible at the holder’s option into two shares of common stock at a $2.50 conversion price, with forced conversion possible after a change in control or specified stock price and financing triggers. Daré may redeem preferred shares any time starting three years after the initial closing at the lower of stated value plus an 8% annual return or 200% of stated value.
The Regulation A offering covers up to 4,854,000 Investor Units at $5.00 per unit, each unit consisting of one preferred share and two warrants to buy common stock at $4.00 per share. The initial closing issued 5,090 Investor Units and related placement compensation, including a 7.25% selling fee and Agent Unit Warrants equal to 3% of units sold.
Daré Bioscience, Inc. reported that it has posted an updated corporate presentation in the Investors section of its website as of January 6, 2026. The same presentation, dated January 6, 2026, is also included as Exhibit 99.1 to this report and incorporated by reference for informational purposes. The company notes that this material is being furnished rather than filed under securities laws, which limits how it is treated for liability and incorporation into other regulatory documents. Information available on or through the company’s website, including the presentation, is not automatically incorporated into this report.
Daré Bioscience reported Q3 2025 results showing minimal revenue and a narrower quarterly loss. Total revenue was $2,262, driven by royalty revenue, while operating expenses fell to $3.67 million, down from $4.72 million a year ago, reflecting lower research and development spending.
Net loss for the quarter was $3.56 million, improving from a $4.70 million loss in Q3 2024. Cash and cash equivalents were $23.08 million at September 30, 2025, up from $15.70 million at year-end, aided by equity financing. The company sold 4,329,116 shares under its March 2023 ATM for gross proceeds of approximately $18.0 million (about $17.6 million net) and 900,000 shares under its Lincoln Park agreement for roughly $2.0 million in net proceeds.
Liquidity remains a key risk. Management disclosed substantial doubt about the company’s ability to continue as a going concern within 12 months, citing ongoing losses, negative operating cash flow, and uncertainty around timing and magnitude of revenue from its Section 503B compounding and consumer health strategies. As of November 12, 2025, 14,289,229 common shares were outstanding.
Daré Bioscience, Inc. (DARE) furnished an update by issuing a press release announcing its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The information is being furnished, not filed, under the Exchange Act, meaning it is not subject to Section 18 liabilities and is not incorporated by reference unless expressly stated. The company’s common stock trades on the Nasdaq Capital Market under the symbol DARE.
Law Custodial Inc. filed a Schedule 13G reporting beneficial ownership of 1,409,167 ordinary shares of Dare Bioscience, Inc., representing approximately 15.9% of the 8,871,155 shares outstanding used for the calculation. The filing states the shares were not acquired to change or influence control and that 795,271 of the shares are held as trustee with sole voting and dispositive power. The reporting person is organized in Samoa with a principal address in Hong Kong and the signature is dated 10/06/2025. This ownership level exceeds 5% and must be disclosed under the Exchange Act.
MarDee Haring-Layton, identified as an officer (Chief Accounting Officer) and director of Dare Bioscience, Inc. (DARE), was granted an employee stock option for 57,000 shares on 09/04/2025 at an exercise price of $2.13. The Form 4 reports the options as beneficially owned directly following the grant, totaling 57,000 shares. The explanatory note states the option is a retention award that vests and becomes exercisable on 09/04/2027, unless certain performance criteria are met earlier, and the table indicates an expiration date of 09/04/2035. The Form is signed by the reporting person on 09/04/2025.
Daré Bioscience, Inc. furnished a new corporate presentation dated September 2, 2025, as Exhibit 99.1 to a current report. The company plans to use this presentation in meetings with securities market participants and others starting on that date.
A copy of the presentation is expected to be made available in the Investors section of Daré Bioscience’s website, on the “Presentations, Events & Webcasts” page under “Presentations.” The company notes that the presentation and the related disclosure are being furnished under Regulation FD and are not considered filed for liability purposes under the Exchange Act or automatically incorporated into other SEC filings.